GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InNexus Biotechnology Inc (GREY:IXSBF) » Definitions » Operating Margin %

IXSBF (InNexus Biotechnology) Operating Margin % : 0.00% (As of Mar. 2011)


View and export this data going back to . Start your Free Trial

What is InNexus Biotechnology Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. InNexus Biotechnology's Operating Income for the three months ended in Mar. 2011 was $-0.32 Mil. InNexus Biotechnology's Revenue for the three months ended in Mar. 2011 was $0.00 Mil. Therefore, InNexus Biotechnology's Operating Margin % for the quarter that ended in Mar. 2011 was 0.00%.

The historical rank and industry rank for InNexus Biotechnology's Operating Margin % or its related term are showing as below:


IXSBF's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -163.19
* Ranked among companies with meaningful Operating Margin % only.

InNexus Biotechnology's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

InNexus Biotechnology's Operating Income for the three months ended in Mar. 2011 was $-0.32 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2011 was $-2.22 Mil.


InNexus Biotechnology Operating Margin % Historical Data

The historical data trend for InNexus Biotechnology's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InNexus Biotechnology Operating Margin % Chart

InNexus Biotechnology Annual Data
Trend Jun01 Jun02 Jun03 Jun04 Jun05 Jun06 Jun07 Jun08 Jun09 Jun10
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5,846.34 -38,700.00 -561,900.00 - -

InNexus Biotechnology Quarterly Data
Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of InNexus Biotechnology's Operating Margin %

For the Biotechnology subindustry, InNexus Biotechnology's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InNexus Biotechnology's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InNexus Biotechnology's Operating Margin % distribution charts can be found below:

* The bar in red indicates where InNexus Biotechnology's Operating Margin % falls into.



InNexus Biotechnology Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

InNexus Biotechnology's Operating Margin % for the fiscal year that ended in Jun. 2010 is calculated as

Operating Margin %=Operating Income (A: Jun. 2010 ) / Revenue (A: Jun. 2010 )
=-3.788 / 0
= %

InNexus Biotechnology's Operating Margin % for the quarter that ended in Mar. 2011 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2011 ) / Revenue (Q: Mar. 2011 )
=-0.316 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InNexus Biotechnology  (GREY:IXSBF) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


InNexus Biotechnology Operating Margin % Related Terms

Thank you for viewing the detailed overview of InNexus Biotechnology's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


InNexus Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
1055 West Georgia Street, 1500 Royal Centre, Vancouver, BC, CAN, V6E 4N7
InNexus Biotechnology Inc is engaged in commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications.

InNexus Biotechnology Headlines

No Headlines